Imaging nigral pathology and clinical progression in Parkinson's disease by Du, Guangwei et al.
Imaging nigral pathology and clinical progression in Parkinson's
disease
Guangwei Du, M.D., Ph.D.1, Mechelle M. Lewis, Ph.D.1,2, Suman Sen, M.D.1, Jianli Wang,
M.D., Ph.D.3, Michele L. Shaffer, Ph.D.7, Martin Styner, Ph.D.8,9, Qing X. Yang, Ph.D.3,4,6,
and Xuemei Huang, M.D., Ph.D.1,2,3,4,5,6,10 [Associate Professor]
1Department of Neurology, Pennsylvania State University-Milton S. Hershey Medical Center,
Hershey PA 17033
2Department of Pharmacology, Pennsylvania State University-Milton S. Hershey Medical Center,
Hershey PA 17033
3Department of Radiology, Pennsylvania State University-Milton S. Hershey Medical Center,
Hershey PA 17033
4Department of Neurosurgery, Pennsylvania State University-Milton S. Hershey Medical Center,
Hershey PA 17033
5Department of Kinesiology, Pennsylvania State University-Milton S. Hershey Medical Center,
Hershey PA 17033
6Department of Bioengineering, Pennsylvania State University-Milton S. Hershey Medical Center,
Hershey PA 17033
7Department of Public Health Sciences, Pennsylvania State University-Milton S. Hershey Medical
Center, Hershey PA 17033
8Department of Computer Science, University of North Carolina, Chapel Hill, NC 27599
9Department of Psychiatry, University of North Carolina, Chapel Hill, NC 27599
10Department of Neurology, University of North Carolina, Chapel Hill, NC 27599
Abstract
Background—The pattern of dopamine cell loss in Parkinson's disease is known to be
prominent in the ventrolateral and caudal substantia nigra, but less severe in the dorsal and rostral
region. Both diffusion tensor imaging and R2* relaxometry of the substantia nigra have been
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reported as potential markers for Parkinson's disease, but their relative ability to mark disease
progression and differences in pathophysiological bases remains unclear.
Methods—High resolution T2-weigthed, R2*, and diffusion tensor imaging were obtained from
28 controls and 40 Parkinson's disease subjects [15 early-stage (disease duration≤1 year), 14 mid-
stage (duration 2-5 years), and 11 late-stage (duration>5 years)]. Fractional anisotropy and R2*
values in both rostral and caudal substantia nigra were obtained for all subjects, and clinical
measures (disease duration; levodopa-equivalent daily dosage; “off”-drug Unified Parkinson's
Disease Rating Scale motor score) were obtained for Parkinson's subjects.
Results—There was no correlation between fractional anisotropy and clinical measures, whereas
R2* was strongly associated with disease progression. Compared to controls, fractional anisotropy
in caudal substantia nigra was significantly decreased in Parkinson's disease patients of all stages,
whereas in rostral substantia nigra it was decreased significantly only in the late-stage group. R2*
in both substantia nigra regions was significantly increased in the mid-stage and late-stage, but not
early-stage, of Parkinson's disease subjects.
Conclusions—These findings suggest that fractional anisotropy changes may mark early
pathological changes in caudal substantia nigra, whereas the changes in R2* may more closely
track Parkinson's disease's clinical progression after symptom onset.
Keywords
Parkinson's disease (PD); substantia nigra; diffusion tensor imaging (DTI); transverse relaxation
rate (R2*); magnetic resonance imaging (MRI)
INTRODUCTION
Parkinson's disease (PD) is marked by the loss of dopaminergic neurons in the substantia
nigra (SN) of the basal ganglia. The neuronal loss is known to occur primarily in the
ventrolateral and caudal region of the SN pars compacta, with less severe pathology in the
dorsal and rostral region.1 This pattern of cell loss was confirmed in another pathological
study that used a different subdivision framework for the SN.2 Both the understanding of the
PD-associated cell loss and the evaluation of potential neuroprotective therapies have been
hindered by the lack of reliable and objective in vivo markers for cell loss and progression in
living human subjects.
Magnetic resonance imaging (MRI) is widely available, and has been explored extensively
to study pathological processes in PD.3-7 For instance, several MRI studies have
demonstrated that effective transverse relaxation rate (R2*=1/T2*) in the SN is correlated
with iron concentration in vivo,4,6,8 and is increased in the SN of PD patients.4,6,9,10
Concomitantly, efforts have been made to apply diffusion tensor imaging (DTI) approaches
to measure microstructure disorganization due to PD-related pathology in the SN.5,7,9,11
Correlation between dopaminergic neuron loss and DTI changes has been reported in
mice.12 Consistent with this, several human studies have demonstrated reduced FA values in
the SN of PD patients.5,7,9,10
Despite the potential of these two promising MRI measurements to mark PD-related
changes in the SN,13 there is neither clear understanding of their relevance to dopamine
neuron death in the SN, nor the clinical signs of PD progression. This is critical for
elucidating the pathophysiological underpinnings of these potential markers, and for
evaluating their utility in both clinical and research settings. Recent data from our laboratory
has suggested that R2* and FA changes in the SN are not correlated, and may reflect
different aspects of PD-related pathological processes.10 To address these issues, the current
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study evaluated the regionally-specific changes of R2* and FA in rostral and caudal regions
of the SN in PD subjects, and their relationship to clinical progression.
Methods
Subjects
Forty PD and 28 healthy control subjects were recruited from a tertiary movement disorders
clinic (see Table 1 for detailed demographic information). Of these subjects, 16 with PD and
16 controls were data that was reported earlier.10 PD diagnosis was confirmed by a
movement disorder specialist (XH) according to published criteria.14,15 Unified Parkinson's
Disease Rating Scale-III motor scores (UPDRS-III) were obtained for each PD subject after
withholding all PD medication overnight (~12 hr), this being an operational “off” stage .16
Levodopa-equivalent daily dose (LEDD) was estimated for PD subjects according to a
published formula.17 All subjects were free of major acute medical issues such as liver,
kidney, or thyroid abnormalities and/or deficiencies of B12 and folate, and all subjects had
Mini Mental Status Exam (MMSE) scores >24. All subjects gave written informed consent
that was reviewed and approved by the Penn State University Institutional Review Board,
and was consistent with the Declaration of Helsinki.
It is believed that the rate of nigrostriatal dopamine neurons and terminals loss in PD is
greatest shortly after diagnosis, but this absolute rate decreases or even plateaus with disease
progression. This slow-down phase typically occurs within 5-10 years of diagnosis18-20 and
may be related to either fewer cells remaining or the presence of dopaminergic cells resistant
to PD-related cell death.18,21 Thus, we categorized PD patients into three clinical stages:
PDES - “early-stage,” newly diagnosed PD subjects within the first year of diagnosis; PDMS
- “mid-stage,” the rapidly progressing stage 2-5 years following diagnosis; and PDL – “late-
stage,” >5 years since initial diagnosis.
Data acquisition
All subjects were scanned with a 3.0 Tesla MRI system (Trio, Siemens Magnetom,
Erlangen, Germany, 8-channel phased array head coil) with high-resolution T2-weighted,
multi-gradient-echoes (T2* weighted), and diffusion tensor imaging (DTI) sequences. A
fast-spin-echo sequence was used to obtain T2-weighted images with TR/TE=2500/316,
FOV=256 mm × 256 mm, matrix=256 × 256, slice thickness=1 mm (with no gap), slice
number=176. A multi-gradient-echo sequence was used to estimate the transverse relaxation
rate, R2* (R2*=1/T2*). Six echoes with TE ranging from 7 to 47 ms and an interval of 8 ms
were acquired with TR=54 ms, flip angle=20°, FOV=256 mm × 256 mm, matrix=256 × 256,
slice thickness=1 mm (with no gap), slice number=64. The middle slice of the multiple
gradient echoes images was placed on the line between the anterior and posterior
commissures (AC and PC, respectively). For DTI, acquisition parameters were as follows:
TR/TE=8300/82 ms, b value=1000 s/mm2, diffusion gradient directions=42 and 7 b=0
scans, FOV=256 mm × 256 mm, matrix=128 × 128, slice thickness=2 mm (with no gap),
slice number=65.
Image processing and analysis
Generation of R2* and DTI maps—The magnitude images of multi-echo SWI images
were used to generate R2* maps by employing a voxel-wise non-linear Levenberg-
Marquardt algorithm to fit a monoexponential function with free baseline using an in-house
MATLAB (The MathWorks, Inc., Natick, MA) tool. DTI image quality control and tensor
reconstruction was done by using DTIPrep (Neuro Image Research and Analysis
Laboratory, University of North Carolina, Chapel Hill, NC) that first checks DWI images
for appropriate quality by calculating the inter-slice and inter-image intra-class correlation,
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and then corrects for the distortions induced by eddy currents and head motion.22 Then,
diffusion tensor maps were estimated via weighted least squares.23 FA, mean diffusivity
(MD), axial diffusivity (AD), and radial diffusivity (RD) maps were finally generated for
subsequent analysis.
Segmentation of substantia nigra—The SN was delineated manually using ITK-
SNAP 24 by an investigator (GD) blinded to subject diagnosis. To obtain a comparable
region-of-interest (ROI) definition with pathological studies,2,25 individual high resolution
T2-weighted images were reformatted by positioning the AC-PC line to the center of the
image and then rotating the AC-PC line 35° superior to the PC point and along the mid-
sagittal plane, as shown in Figure 1A. The 35° rotation was used to minimize the inclusion
of the subthalamic nucleus that lays superior-anterolateral to the SN.26,27 The SN was
defined as a hypo-intensity band between the red nucleus and cerebral peduncle in axial
sections on multi-planar reformatted T2-weighted images as illustrated in Figure 1.
Segmentation of the SN was started at one slice lower than the level of the red nucleus
showing the largest radius and is shown as the yellow band in Figure 1A. The relationship of
the SN, red nucleus, and subthalamic nucleus is depicted in Figure 1B. A total of six slices
(from the rostral to caudal part of the SN) were used as the SN ROI (Figure 1C). The first
three slices were treated as the rostral SN segment and the remaining three slices were
considered the caudal segment. Figures 1D 1-6 show the six slices segmented for the SN
starting with the most rostral slice (Figure 1D 1) and gradually growing the SN ROI to
include the more caudal region (Figure 1D 2-6). All ROIs then were visually assessed by a
second trained neuroscientist blinded to subject diagnosis to validate and fix potential
mislabeling of the SN definition.
After manual segmentation, the ROIs were mapped to R2* and FA maps, respectively, by
co-registering the T2-weighted images to R2* maps and the B0 images of DTI data by an
affine registration followed with a b-spline non-rigid registration implemented in 3D Slicer
(www.slicer.org).28 R2* and DTI (FA, MD, AD, and RD) values in both the rostral and
caudal segments of the SN of each subject were calculated using trimmed means (from the
5%-95% percentile) to reduce variability introduced by manual segmentation and imperfect
registration processes.
Statistical Analysis
PD and Control demographics were compared using two-sample t-tests and Fisher's exact
tests as appropriate. The association between clinical (disease duration, LEDD, and “off”
drug UPDRS-III scores) and Regional MRI measures (R2* and DTI) was quantified via
partial Pearson correlation coefficient analysis with adjustment for age. R2* and DTI values
were compared separately between PD and control subjects by analysis of covariance
(ANCOVA) with adjustments for age and gender. PD subgroups and control subjects also
were compared using ANCOVA with adjustments for age and gender. All statistical
analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Demographics
The demographic and clinical data are summarized in Table 1. Although there were no
significant differences in age or gender between the overall PD group and control subjects or
among controls and the PD subgroups, there were more males in the PD group and more
females in the controls, reflecting the fact that PD is more common in males and many
controls were spouses of PD patients. Because the exact effects of gender on PD and disease
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progression are unknown, we have adjusted for gender in all means comparisons as reported
below.
DTI results
The PD subjects overall had significantly reduced FA values in both rostral and caudal
segments of the SN compared to control subjects, the FA decrease in the caudal region
seemed to be more robust than the rostral region [p=0.020 for rostral SN, p<0.001 for caudal
SN, Table 2]. In addition, FA values showed a different pattern of change between the
rostral and caudal regions of the SN across the PD subgroups. Namely, FA value decreases
did not reach significance until the very late stage of PD (PDLS subgroup) for the rostral SN,
whereas in the caudal region significant decreases were evident in the very early stage of the
disease (PDES subgroup, see Table 2). Although there appears to be a linear trend of FA
decreasing across PD subgroups (Figure 2), there was no statistically significant difference
among PD subgroups. The results of analyses of MD, AD, and RD values are presented in
Supplemental Table 1, and indicated that only RD in the caudal SN showed a significant
increase in the overall PD group and the PDLS subgroup when compared to Controls.
R2* results
PD subjects, as a whole, had significantly increased R2* values in both rostral and caudal
segments of the SN compared to control subjects [p<0.001 in both segments, Table 2]. In
contrast to the FA results, R2* values showed a similar pattern in both the rostral and caudal
regions of the SN in PD subgroup analyses (see Figure 2). Namely, there was only a
marginal increase in R2* values in the PDES subgroup [p=0.050 for rostral SN, p=0.094 for
caudal SN], that then reached significance in the PDMS subgroup [p=0.012 for rostral SN,
p=0.004 for caudal SN], and was even more significant in the PDLS subgroup [p<0.001 for
both SN regions]. There also were significant differences between PDES and PDLS
[p=0.013] subgroups in the caudal region of the SN, with a trend observed in the rostral
region [p=0.053].
Relationship of imaging and clinical values
None of the clinical measurements were associated with FA values (third and fourth rows in
Figure 3). Conversely, R2* values from the caudal region of the SN were significantly
correlated with all three clinical measures (second row graphs in Figure 3), whereas R2* in
the rostral area were correlated only with UPDRS-III scores (first row graphs in Figure 3).
Discussion
In the past, DTI and R2* in the SN have each been hypothesized to be useful in assisting
with the diagnosis of PD and gauging its progression.3-7 We previously found a lack of a
correlation between R2* and FA, although combined R2* and FA measurements in the SN
may increase the discrimination between PDs and Controls.10 One implication of these prior
data is that that these two MRI measurements reflect different pathological processes in the
SN. The results of the current study are consistent with this hypothesis, and are the first to
show that SN FA and R2* changes follow different temporal and spatial (dorsal and caudal)
patterns in PD. Namely, FA changes in the caudal SN were present at the time of disease
diagnosis, but did not capture the clinical progression thereafter. Conversely, R2* changes in
both SN regions were not obvious until later disease stages, but correlated significantly with
all clinical measures.
Histopathological studies have shown that there is a specific temporal and spatial pattern of
SN neuron loss in PD. Temporally, this loss follows an exponential course that gradually
decreases with disease progression.1 Spatially, more than 90% of cells in the caudal region
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are lost at the onset of motor symptoms, whereas only ~50% are lost in the rostral region.1,2
In the present study, the FA changes are consistent with the spatial and temporal pattern of
dopaminergic cell loss reported in pathological studies. Namely, FA changes were evident
very early in the disease (around the time of diagnosis), most significantly in the caudal
region of the SN, and seemed not to capture disease progression. The spatial finding of FA
changes in early-stage PD is consistent with the results of a previous imaging study by
Vaillancourt et al.7 that showed decreased FA values in the caudal, but not rostral, area of
the SN in early-stage PD patients. In our study, SN FA changes did not correlate
significantly with any clinical measurements as was noted earlier.9 The lack of a correlation
between FA values and clinical measurements of disease progression may be due to the
asymptotic nature of cell loss, and/or the limited FA sensitivity to detect subtle changes
related to progressive loss of the remaining ~10% of neurons in the caudal region.
Collectively, these data underscore the need for future testing of the hypothesis that FA
changes in the SN may be a reflection of neuronal loss and consequential tissue
microstructure damage in the SN, and may have potential for pre-symptomatic screening.
Our R2* data in the SN strongly discriminated PD and controls, consistent with previous
studies.6,9,10 More interestingly, we found a significant correlation between SN R2* values
and all clinical measurements of PD. This is consistent with the hypothesis that R2* in the
SN may be used as a quantitative marker for disease progression.6,9 Unlike FA changes, the
R2* changes in the SN did not follow the temporal and spatial patterns reported for
dopaminergic cell death as delineated in past pathological studies.1,2 Temporally, R2*
changes were not obvious in early-stage PD subjects, but only became significant later in the
disease. Spatially, similar R2* changes were observed in both caudal and rostral regions of
the SN. This pattern discrepancy between R2* and dopaminergic cell loss suggests that R2*
values may not be a good marker for dopaminergic cell loss.
Although the exact mechanism of the R2* changes in PD is unknown, there are two
potential explanations for the R2* value changes and its clinical associations in PD. First, it
is possible that the R2* value may be an indicator of the oxidative stress related to excessive
iron deposition,29-32 suggesting that R2* may be a surrogate marker for PD-related
etiological mechanism(s). Alternatively, R2* is known to be altered by complex factors
(e.g., ferric iron and amyloid plaques, ferritin and hemosiderin, and calcium deposition) that
create magnetic field inhomogeneity.33-36 The presence of a significant correlation between
SN R2* values and all clinical measurements after diagnosis also may suggest that R2*
reflects iron homeostasis determined by PD-related iron accumulation although we cannot
exclude epiphenomena such as treatment-induced metabolic changes. Increased iron content
in the SN has been observed in the most severe PD cases, but not in milder or
presymptomatic PD cases.37,38 The fact that we detected significant SN R2* changes only in
later disease stages subjects is consistent with the hypothesis that R2* reflects SN iron
accumulation. Neuromelanin plays an important role in iron homeostasis39 and an iron-
neuromelanin interaction in the SN is observed in PD postmortem brain tissue.40,41 T1-
weighted MRI was suggested to reflect SN neuromelanin content, and recently reported to
change in a disease stage-dependent manner in PD.42 Combining these two MRI
measurements in future studies may provide insight on the in vivo dynamic changes in iron
homeostasis in the PD process.
Unlike previous studies,6,7 we developed a semi-automated protocol to define SN
subregions on both R2* and FA images, one that provided a robust method for reducing the
variability introduced by manual segmentation in different MRI modalities. Definition of the
SN in MR images remains controversial.6,43-45 Instead of separating the SN into the pars
compacta and pars reticulata, we delineated the rostral and caudal SN because this is most
comparable to previous pathology studies.1,2 Moreover, in the data analysis, PD subjects
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were divided into three disease duration subgroups to capture better the known pattern of
PD-related dopaminergic cell progression,1,20 thus providing increased power for detecting
potential temporal correlations between these two MRI measurements and PD progression.
There are some limitations in the present study. For example, the sample size of the current
study is relatively small for a cross-sectional observational study. The spatial resolution of
the DTI images in the study is 2×2×2 mm, lower than that for the R2* images (1×1×1 mm).
Therefore, the power of FA values in predicting PD may be underestimated, and may
explain why we did not achieve as great a discrimination between PD and controls as did
Vaillancourt et al.7 Emerging 7T MRI data may provide better spatial resolution and
increased sensitivity to detect iron in the SN. Indeed, 7T SWI recently was effective in
differentiating PDs from controls,46 and may be integrated into MRI biomarker research
once it becomes more accessible.
In summary, this study is consistent with the hypothesis that FA and R2* values in the SN
reflect different aspects of PD-related pathology and/or concomitant epiphenomena. As FA
is thought to reflect the microstructural integrity of a region, its change in the caudal SN in
early PD may indicate existing and significant PD-related microstructural alterations in this
area, and may be useful for early PD detection. R2* values, on the other hand, may reflect
iron homeostasis and/or other metabolic/biochemical changes occurring during disease
progression in PD and may be useful as an objective marker for PD progression. Further
studies with drug-naïve subjects, larger sample size and longitudinal design, and
histopathological correlations are warranted to test these hypotheses and investigate the
detailed pathological underpinnings of these two in vivo MRI markers in PD and their utility
in clinical practice and research studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Procedure used to segment the rostral and caudal regions of the SN. A: Illustration of the
position of slices used for the definitin of ROIs. B and C: Illustration of the three dimesional
relationship of the ROIs and the separation of the rostral and caudal regions of the SN.
D(1-6): Illustration of the exact locations of the SN ROI.
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Correlations between clinical measurements and MRI measurements. The scatterplots depict
the age-adjusted residuals. The shaded areas represent the 95% confidence interval for each
regression line.
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Comparison of R2* and FA values in different segments of the SN in PDs and Controls.
Error bars represent the SEM. PDES - “early-stage,” are newly diagnosed PD subjects within
the first year of diagnosis; PDMS - “mid-stage,” are those that are in the rapidly progressing
stage, 2-5 years following diagnosis; and PDL – “late-stage,” are PD subjects who are >5
years since initial diagnosis.. Signficant differences between PD and control subjects are
represented as: *: p<0.05; ***: p<0.001.
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